Excerpt
To the Editor:
We read with interest the article by Baraliakos, et al concerning no increase in incidence of infusion reactions after infliximab readministration in patients with ankylosing spondylitis1. In some rheumatoid arthritis (RA) cases, this treatment has to be discontinued due to infusion reactions2. Overall, the incidence of infusion reaction to infliximab is about 5% of cases in Crohn’s disease (CD)3,4, and as recently reported, when combined with glucocorticoid therapy, from 4.6% to 8.6% in RA5. Further, delayed infusion reactions in CD were reported in 25% of patients who received infliximab again after a 2–4 year interval without…